PharmaCyte Biotech, Inc.
PMCB
$1.19
$0.043.48%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -51.66% | -23.96% | -40.49% | 31.15% | 15.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.62% | -21.47% | -38.86% | 29.10% | 20.34% |
| Operating Income | 48.62% | 21.47% | 38.86% | -29.10% | -20.34% |
| Income Before Tax | -391.57% | -152.68% | 835.76% | 1,166.27% | 18.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -391.57% | -152.68% | 835.76% | 1,166.27% | 18.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -391.57% | -152.68% | 835.76% | 1,166.27% | 18.92% |
| EBIT | 48.62% | 21.47% | 38.86% | -29.10% | -20.34% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 33.00% | 17.82% | 506.19% | -4,184.51% | -1,524.38% |
| Normalized Basic EPS | 720.00% | 15.03% | 165.48% | 5,793.18% | -79.28% |
| EPS Diluted | 33.00% | 17.82% | 506.19% | -4,184.51% | -1,524.38% |
| Normalized Diluted EPS | 720.00% | 15.03% | 165.48% | 5,793.18% | -79.28% |
| Average Basic Shares Outstanding | -19.14% | -12.87% | -37.58% | -53.09% | -54.69% |
| Average Diluted Shares Outstanding | -19.14% | -12.87% | -37.58% | -53.09% | -54.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |